Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

The Pharma Data

NOVEMBER 26, 2020

Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market. The benefits of developing a patient-centric clinical supply chain. Add bookmark.

Clinical Trials 52

Clinical Trials Marketing Trials Clinical Supply 52

LifeSciVC

AUGUST 21, 2024

This is especially true for rare disease trials with so few patients or trials involving patients with numerous concomitant or life-threatening conditions. can have a significant impact on manufacturing timelines and drug supply chains. vacations, which are typically more ‘off the grid’ than in the U.S.,

Clinical Trials 77

Clinical Trials Trials Disease Treatment 77

The Pharma Data

JANUARY 10, 2021

About MorphoSys MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for patients suffering from cancer and autoimmune diseases.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Supply Trials 52

The Pharma Data

NOVEMBER 22, 2020

. “In collaboration with our partner, Novartis, our team continues to move at extraordinary speed from idea to bench to clinical trials, driven by a common desire to help patients against this devastating disease and help bring the world back closer to normalcy.” million doses of MP0420, if it is approved in Switzerland.

Trials 40

Trials Clinical Trials Licensing Licensing 40

The Pharma Data

NOVEMBER 18, 2020

Results of preclinical studies demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models published in Journal of Nuclear Medicine. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. Financial Highlights.

Trials 40

Trials Clinical Supply Production Therapies 40

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.

Disease 52

Disease FDA Treatment Clinical Trials 52